AmpliPhi: Advancing Bacteriophage For The Treatment Of Bacterial Infections




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AmpliPhi: Advancing Bacteriophage For The Treatment Of Bacterial Infections
Released on: December 15, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    AmpliPhi Biosciences (NYSEMKT: APHB) is a biotechnology company focused on the development of a pipeline of naturally occurring viruses called bacteriophages, the natural predators of bacteria.
  • Summary
  • Participants
  • Company
AmpliPhi Biosciences (NYSEMKT: APHB) is a biotechnology company focused on the development of a pipeline of naturally occurring viruses called bacteriophages, the natural predators of bacteria. Phages have evolved alongside their bacterial prey; resulting in both precise and highly effective bacterial killing mechanisms. Adrian Dawkes discusses with Matt Dansey how Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections, in particular, drug-resistant strains of bacteria commonly found in chronically infected patients.
Matt Dansey, Manager of Business Development
Bacterial resistance to antibiotics is increasing and will continue to rise if alternative therapies are not developed. The threat is very real and we may face mortality rates encountered in the pre-antibiotic era due to drug-resistant bacterial infections. AmpliPhi Biosciences is harnessing the power of bacteriophages – viruses that infect and kill only bacteria – to provide alternatives to antibiotics, which will result in better controlled infections, fewer side effects and targeted treatments.